246 related articles for article (PubMed ID: 29494632)
21. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.
Adam A; Montpas N; Keire D; Désormeaux A; Brown NJ; Marceau F; Westenberger B
Biomaterials; 2010 Aug; 31(22):5741-8. PubMed ID: 20427081
[TBL] [Abstract][Full Text] [Related]
22. The tainted heparin story: an update.
Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
[TBL] [Abstract][Full Text] [Related]
23. Venous and arterial thrombosis in rat models: dissociation of the antithrombotic effects of glycosaminoglycans.
Zancan P; Mourão PA
Blood Coagul Fibrinolysis; 2004 Jan; 15(1):45-54. PubMed ID: 15166943
[TBL] [Abstract][Full Text] [Related]
24. Purification, structural characterization and anticoagulant properties of fucosylated chondroitin sulfate isolated from Holothuria mexicana.
Mou J; Wang C; Li W; Yang J
Int J Biol Macromol; 2017 May; 98():208-215. PubMed ID: 28153461
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of Fucosylated Chondroitin Sulfate Glycoclusters: A Robust Route to New Anticoagulant Agents.
Zhang X; Yao W; Xu X; Sun H; Zhao J; Meng X; Wu M; Li Z
Chemistry; 2018 Feb; 24(7):1694-1700. PubMed ID: 29131431
[TBL] [Abstract][Full Text] [Related]
26. A unique dermatan sulfate-like glycosaminoglycan from ascidian. Its structure and the effect of its unusual sulfation pattern on anticoagulant activity.
Pavão MS; Mourão PA; Mulloy B; Tollefsen DM
J Biol Chem; 1995 Dec; 270(52):31027-36. PubMed ID: 8537360
[TBL] [Abstract][Full Text] [Related]
27. Complement C1 esterase inhibitor levels linked to infections and contaminated heparin-associated adverse events.
Zhou ZH; Chen T; Arora K; Hyams K; Kozlowski S
PLoS One; 2012; 7(4):e34978. PubMed ID: 22514695
[TBL] [Abstract][Full Text] [Related]
28. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications.
Ramacciotti E; Clark M; Sadeghi N; Hoppensteadt D; Thethi I; Gomes M; Fareed J
Clin Appl Thromb Hemost; 2011 Apr; 17(2):126-35. PubMed ID: 21288929
[TBL] [Abstract][Full Text] [Related]
29. Anticoagulant and antithrombotic evaluation of native fucosylated chondroitin sulfates and their derivatives as selective inhibitors of intrinsic factor Xase.
Wu M; Wen D; Gao N; Xiao C; Yang L; Xu L; Lian W; Peng W; Jiang J; Zhao J
Eur J Med Chem; 2015 Mar; 92():257-69. PubMed ID: 25559206
[TBL] [Abstract][Full Text] [Related]
30. Structure and anticoagulant properties of sulfated glycosaminoglycans from primitive Chordates.
Pavão MS
An Acad Bras Cienc; 2002 Mar; 74(1):105-12. PubMed ID: 11960179
[TBL] [Abstract][Full Text] [Related]
31. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes.
Warkentin TE; Greinacher A
Expert Opin Drug Saf; 2009 Mar; 8(2):129-44. PubMed ID: 19309242
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and detection of N-sulfonated oversulfated chondroitin sulfate in marketplace heparin.
Mans DJ; Ye H; Dunn JD; Kolinski RE; Long DS; Phatak NL; Ghasriani H; Buhse LF; Kauffman JF; Keire DA
Anal Biochem; 2015 Dec; 490():52-4. PubMed ID: 26278168
[TBL] [Abstract][Full Text] [Related]
33. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market.
Beyer T; Matz M; Brinz D; Rädler O; Wolf B; Norwig J; Baumann K; Alban S; Holzgrabe U
Eur J Pharm Sci; 2010 Jul; 40(4):297-304. PubMed ID: 20399266
[TBL] [Abstract][Full Text] [Related]
34. The use of circular dichroism as a simple heparin-screening strategy.
Stanley FE; Stalcup AM
Anal Bioanal Chem; 2011 Jan; 399(2):701-6. PubMed ID: 20953771
[TBL] [Abstract][Full Text] [Related]
35. Chemical Fucosylation of a Polysaccharide: A Semisynthetic Access to Fucosylated Chondroitin Sulfate.
Laezza A; Iadonisi A; Castro CD; De Rosa M; Schiraldi C; Parrilli M; Bedini E
Biomacromolecules; 2015 Jul; 16(7):2237-45. PubMed ID: 26083095
[TBL] [Abstract][Full Text] [Related]
36. Orthogonal analytical approaches to detect potential contaminants in heparin.
Guerrini M; Zhang Z; Shriver Z; Naggi A; Masuko S; Langer R; Casu B; Linhardt RJ; Torri G; Sasisekharan R
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16956-61. PubMed ID: 19805108
[TBL] [Abstract][Full Text] [Related]
37. Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations.
Volpi N; Maccari F; Linhardt RJ
Anal Biochem; 2009 May; 388(1):140-5. PubMed ID: 19232311
[TBL] [Abstract][Full Text] [Related]
38. Structural requirements of Holothuria floridana fucosylated chondroitin sulfate oligosaccharides in anti-SARS-CoV-2 and anticoagulant activities.
Farrag M; Dwivedi R; Sharma P; Kumar D; Tandon R; Pomin VH
PLoS One; 2023; 18(5):e0285539. PubMed ID: 37167245
[TBL] [Abstract][Full Text] [Related]
39. A Study for the Access to a Semi-synthetic Regioisomer of Natural Fucosylated Chondroitin Sulfate with Fucosyl Branches on
Vessella G; Traboni S; Pirozzi AVA; Laezza A; Iadonisi A; Schiraldi C; Bedini E
Mar Drugs; 2019 Nov; 17(12):. PubMed ID: 31766509
[TBL] [Abstract][Full Text] [Related]
40. A Modular Approach to a Library of Semi-Synthetic Fucosylated Chondroitin Sulfate Polysaccharides with Different Sulfation and Fucosylation Patterns.
Laezza A; Iadonisi A; Pirozzi AV; Diana P; De Rosa M; Schiraldi C; Parrilli M; Bedini E
Chemistry; 2016 Dec; 22(50):18215-18226. PubMed ID: 27797117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
